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Novelty and impact
 Ever use of OCs was positively associated with melanoma risk, with no heterogeneity 
across European countries and a positive linear association with duration of use.
 Ever use of MHT was associated with a modest increase in melanoma risk overall. 
This association was heterogeneous across countries, which may reflect confounding 
by behavioral factors.
 More research is needed to investigate potential confounding or effect modification 
of sun exposure on these relations.
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Abstract
Evidence suggests an influence of sex hormones on cutaneous melanoma risk, but 
epidemiologic findings are conflicting. We examined the associations between use of oral 
contraceptives (OCs) and menopausal hormone therapy (MHT) and melanoma risk in women 
participating in the European Prospective Investigation into Cancer and Nutrition (EPIC). EPIC 
is a prospective cohort study initiated in 1992 in 10 European countries. Information on 
exogenous hormone use at baseline was derived from country-specific self-administered 
questionnaires. We used Cox proportional hazards regression models to calculate hazard 
ratios (HRs) and 95% confidence intervals (CIs). Over 1992-2015, 1,696 melanoma cases 
were identified among 334,483 women, whereof 770 cases among 134,758 postmenopausal 
women. There was a positive, borderline-significant association between OC use and 
melanoma risk (HR=1.12, 95% CI=1.00-1.26), with no detected heterogeneity across 
countries (Phomogeneity=0.42). This risk increased linearly with duration of use (Ptrend=0.01). 
Among postmenopausal women, ever use of MHT was associated with a non-significant 
increase in melanoma risk overall (HR=1.14, 95% CI=0.97-1.43), which was heterogeneous 
across countries (Phomogeneity=0.05). Our findings do not support a strong and direct 
association between exogenous hormone use and melanoma risk. In order to better 
understand these relations, further research should be performed using prospectively 
collected data including detailed information on types of hormone, and on sun exposure, 
which may act as an important confounder or effect modifier on these relations.
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Introduction
Cutaneous melanoma is the most lethal form of skin cancer, leading to more than 55,000 
deaths annually worldwide (1,2). Established risk factors for this neoplasm include ultraviolet 
radiation (UV) exposure, pigmentary traits, and familial history of skin cancer (2,3). Among 
other factors under investigation, sex hormones have been suspected to influence 
melanoma risk. Case reports documented progression or worse prognosis of melanomas 
diagnosed during pregnancy (4–7), and sex steroids have been shown to influence cutaneous 
pigmentation (8). Epidemiologic trends show a higher melanoma incidence in females 
compared with males under age 55 (9), and women were consistently reported to have 
higher survival rates (10) and lower risks of mortality and metastasis (11) compared with 
men, regardless of tumor stage, histologic type, or anatomic site (10,12). Several 
epidemiologic studies reported associations between melanoma risk and reproductive and 
menstrual factors (including in the French E3N cohort (13)), some of which were confirmed 
in a 2011 meta-analysis (14).
Among hormonal exposures, oral contraceptives (OCs) and menopausal hormone therapy 
(MHT) represent a considerable source of exogenous hormone exposure. Various 
formulations have been developed over past decades, with different uses across countries. 
Overall, oral hormones remain the leading contraception method in industrialized countries 
(15), whereas MHT use decreased in the 2000s following the findings from the Women’s 
Health Initiative trial, which showed increased breast cancer and cardiovascular risks in users 
of combined MHT (16,17).
The use of OCs and MHT has been associated with a higher risk of several cancers, including 
in the EPIC cohort (breast (18–20), cervical (21), and endometrial cancer (22,23), and 
meningioma (24)), and estrogen-only and combined estrogen-progestin hormonal therapy 
has been classified as carcinogenic to humans (Group 1) by the International Agency for 
Research on Cancer (IARC)(15,25). With regards to melanoma, while several studies reported 
a higher melanoma risk associated with exogenous hormone use (26–31), findings are 
inconsistent to date. A meta-analysis concluded to no association between exogenous 
hormone use and melanoma risk (14); however, previous studies were heterogeneous, and 
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few were based on a prospective design. In addition, although melanoma has been shown to 
be a heterogeneous tumor (32,33), very few studies explored the associations between 
exogenous hormone use and melanoma risk according to tumor site or histologic type. 
Moreover, the cumulative use of both OC and MHT over time has been suggested to 
increase melanoma risk (30), but only one study examined this issue to date and it was 
based on a limited duration of use.
Our aim was to explore the use of OC and MHT in relation to melanoma risk in the large 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort.
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Materials and Methods
EPIC is a multicenter prospective cohort study involving 521,330 participants 
(367,903 women) who were recruited in 1992-2000 from 23 centers across 10 European 
countries (France, Italy, Spain, the United Kingdom, the Netherlands, Greece, Germany, 
Sweden, Denmark, and Norway). Complete descriptions of the cohort and data collection 
have been published previously (34). All participants gave written informed consent, and the 
Ethical Review Board of IARC and ethical committees from all participating centers approved 
the study.
Study population
We included only participants without a prevalent cancer at baseline (n=491,992). We then 
excluded men (n=148,007) and women with primary amenorrhea (n=43). For analyses on 
OCs, we further excluded women with missing information on OC use (n=9,459), leading to a 
study sample of 334,483 women. Analyses on MHT were restricted to women who were 
postmenopausal at baseline (n=160,025). Postmenopausal women from the Swedish 
(n=14,146) and Greek (n=8,838) cohorts were not included because of lack of data on MHT, 
and we further excluded 2,283 women who reported no information on MHT or OC use, 
leaving a final sample of 134,758 postmenopausal women for the MHT analyses.
Menopausal status was based on an algorithm previously used (18): women were 
considered postmenopausal if they reported 12 consecutive months of amenorrhea or 
bilateral oophorectomy. Women for whom menopause was obscured by hysterectomy, 
those who were still menstruating and using exogenous hormones, and women with no 
information on number of menses over the 12 months preceding baseline were considered 
postmenopausal if they were 55 years or older.
Identification of melanoma cases and follow-up
The identification of incident cancers and determination of vital status during follow-up 
were conducted using a combination of methods including linkage with population cancer 
and pathology registries, health insurance and hospital discharge records, national and 
regional mortality registries, and active follow-up through contacts with participants and 
their next-of-kin. The outcome was incident cutaneous melanoma (site codes ICD-O-2, code 
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C44), with no consideration of mucosal tumors. We considered both in situ and invasive 
tumors (morphology behavioral codes 2 and 3, respectively). Women were followed up from 
study entry until first diagnosis of incident cancer (except non-melanoma skin cancer), 
death, loss to follow-up, or end of follow-up period, whichever occurred first. The follow-up 
period ended between June 2008 and December 2013, depending on the center.
Exposure assessment
Information on hormone use was derived from country-specific questionnaire items, which 
covered questions on ever use of OC, age at first use, and duration of use. Information on 
MHT use included ever and current use, age at first use, duration of use, and brand name of 
MHT currently used at recruitment. From the MHT brand name, we could deduce the type of 
hormone and the route of administration, and for combined MHT, the regimen - defined as 
sequential (estrogen with added progestin 10-14 days a month) or fixed continuous 
(estrogen with added progestin daily).
Statistical analysis
We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 
95% confidence intervals (CIs), with age as time scale. Models were first stratified by center 
to control for different follow-up procedures and questionnaire design across centers, and 
by age at recruitment (in 1-year intervals) (Model 1), then further adjusted for potential 
confounders that were recorded in all countries: education (none/primary, 
technical/professional school, secondary school, longer education, missing), age at 
menarche (≤12 years, 13-14, ≥15 years, missing), mean length of menstrual cycles (<30 days, 
30-33, 34-36, ≥37 days, missing), number of full-term pregnancies (none, one, two, three or 
more, missing), OC use (ever, never; for analyses on MHT), menopausal status 
(premenopausal, postmenopausal; for analyses on OCs), height (quartiles), body mass index 
(<18.5, 18.5-24, 25-29, ≥30 kg/m2), and smoking status (never, former, current smoker, 
missing) (Model 2). Sensitivity analyses were performed with adjustment for additional 
factors, excluding countries for which covariates were not fully available (Norway, Denmark, 
Spain, Greece, Sweden, representing a total sample size of n=209,461 for analyses on OC, 
and n=92,489 for analyses on MHT). Model 3 was additionally adjusted for hours of 
recreational physical activity in summer (number of hours of walking, cycling, gardening, and 
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physical exercise in a typical week during the past year: below or above the median (10 
hours), missing), which we used as a proxy for recreational sun exposure. Model 4 was based 
on Model 3, with additional adjustment for marital status (single, married/living together, 
divorced/separated, widowed, missing). For analyses on OCs, two additional models were 
built: Model 5 was based on Model 2 and additionally adjusted for MHT use 
(premenopausal, postmenopausal ever user of MHT, postmenopausal never user of MHT). In 
Model 6, all covariates were included (Model 2 additionally adjusted for physical activity 
during summer, marital status, and MHT use). Tests for homogeneity were performed using 
Wald chi-square tests to compare MHT formulations, and Q tests to compare estimates 
across countries. To address a potential reverse causality bias, ever use of exogenous 
hormones were also analyzed in relation to melanoma risk after excluding cases diagnosed 
within 1 year after baseline (n=108 for OC analysis and n=45 for MHT analysis).
We also tested for effect modification by factors associated with melanoma risk in our study 
sample (i.e. education, marital status, physical activity during summer, and height).
Melanoma risk was also analyzed according to histologic subtype and anatomic site using 
competing-risk models with the cause-specific hazards approach (35,36). Cases with missing 
information on anatomic site or histologic subtype were excluded from these analyses. We 
tested for heterogeneity between subtypes and sites using Q tests.
Analyses were performed using the SAS statistical software package (version 9.4).
Data availability
The data that support the findings of this study are available on request from the 
corresponding author. The data are not publicly available due to privacy or ethical 
restrictions.
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Results
A total of 1,696 incident cases of melanoma (including 136 in situ) were ascertained among 
334,483 women for the OC analysis, and 770 incident cases (including 94 in situ) among 
134,758 postmenopausal women for the MHT analysis. The incidence of melanoma was 
highest in Sweden and the Netherlands, with 48 and 46 cases per 100,000 person-years, 
respectively; and lowest in Greece, where the incidence was 8 per 100,000 person-years. 
Among melanomas with available information on histology, most were of the superficial 
spreading type (SSM, 73%). The most frequent body site of the tumor was the lower limbs 
(42%).
Table 1 presents the characteristics of participants at baseline. Most women reported to 
have ever used OCs or MHT, except in Italy, Spain, and Greece where OC or MHT use was 
markedly less common. Use of both treatments was highest in Germany (44%) and Norway 
(42%). Patterns of use varied across countries (Table 2). Among current MHT users, opposed 
estrogens were more frequent in France and Norway than in other countries; and while 
progesterone derivatives were mainly used to oppose estrogen in France, Italy, and Spain, 
other countries mainly used testosterone derivatives.
In Model 2, there was a modest positive association between ever use of OCs and melanoma 
risk (HR=1.12, 95% CI=1.00-1.26) (Table 3) and we observed no heterogeneity in estimates 
across countries (Phomogeneity=0.42) (Supplementary table 1). There was also a positive linear 
association with duration of use (≤5 years: HR=1.11, 95% CI=0.97-1.26; >5 years: HR=1.20, 
95% CI=1.04-1.37 vs. never use, Ptrend=0.01). However, there was no association with age at 
first OC use (Ptrend=0.19). In sensitivity analyses using a restricted sample (n=209,461), 
associations remained stable across adjustment models, although statistical significance was 
lost with additional adjustment (Supplementary table 2).
There was a modest positive association between ever use of MHT and melanoma risk 
(HR=1.14, 95% CI=0.97-1.35 in Model 2) (Table 4). However, there was heterogeneity in 
estimates across countries (Phomogeneity=0.005): we observed increased risks for ever vs. never 
use in France (HR=1.69, 95% CI=1.18-2.42), Spain (HR=2.48, 95% CI=0.99-6.22), and Germany 
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(HR=2.75, 95% CI=1.22-6.21) but not in other countries (Supplementary table 1). In 
sensitivity analyses using a restricted sample (n=92,489), the association between ever use 
of MHT and melanoma risk was stronger and statistically significant (HR=1.32, 95% CI=1.08-
1.62 in Model 2), but remained stable after adjustment for marital status and hours of 
physical activity in summer (Supplementary table 3). 
We found no association between duration of MHT use or age at first use and melanoma risk 
(Table 4). Nevertheless, when considering MHT type, estradiol was positively associated with 
melanoma risk (HR=1.53, 95% CI=1.11-2.11), albeit with no heterogeneity across estrogen 
types (Phomogeneity=0.18). Unopposed estrogens administrated by cream (HR=2.20, 95% 
CI=1.12-4.29) were also associated with a higher risk. Also, while we found no heterogeneity 
across types of progestogens (Phomogeneity=0.16), among combined MHTs, those containing 
promegestone were positively associated with melanoma risk (HR=2.57, 95% CI=1.44-4.60 in 
Model 2). However, we found no association with type of regimen (sequential or fixed 
continuous). Of note, in sensitivity analyses, all these results remained stable across 
adjustment models (Supplementary table 3). Nevertheless, the association with MHT 
seemed stronger with higher durations of use (HR=1.32, 95% CI=0.94-1.85 for MHT use >5 
years vs. no use in Model 2), and for norethindrone-containing MHTs (HR=1.88, 95% CI=1.16-
3.06) and sequential regimens (HR=1.61, 95% CI=1.08-2.42).
We found no effect modification for ever use of exogenous hormones and melanoma risk by 
height, body mass index, marital status, hours of physical activity during summer, or 
education level on melanoma risk. Also, estimates were not substantially modified after 
exclusion of cases diagnosed within the first year of follow-up (ever use of OCs: HR=1.12, 
95% CI=0.99-1.26; ever use of MHT: HR=1.12, 95% CI=0.95-1.33).
When exploring the cumulative use of OCs and MHT among postmenopausal women, we 
found no additional risk in women who have ever used OCs and not MHT, MHT and not OCs, 
or who used both treatments over their lifetime (Table 5). There was also no association 
between the combined duration of both treatments and melanoma risk. However, in 
sensitivity analyses, MHT users were at higher melanoma risk, with or without OC use, 
compared with women who never used hormonal therapies (never use of OCs: HR=1.30, 
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95% CI=1.00-1.70; ever use of OCs: HR=1.31, 95% CI=1.00-1.72, in Model 4) (Supplementary 
table 4).
In type- and site-specific analyses, the positive association between OC use and melanoma 
risk was restricted to the acro-lentiginous melanoma subtype (ALM: HR=3.24, 95% CI=1.24-
8.48; Phomogeneity=0.05) (Supplementary table 5). The association between OC use and 
melanoma risk seemed stronger for tumors on the lower limbs, and the association between 
MHT use and melanoma seemed stronger for the ALM and lentigo maligna subtypes, and for 
head and neck tumors, albeit with no evidence for heterogeneity (Phomogeneity=0.98, 0.36, and 
0.56, respectively).
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Discussion
This prospective cohort study is one of the largest to date on the associations between 
exogenous hormone use and melanoma risk. Use of OCs was positively associated with 
melanoma risk, with no evidence of heterogeneity across countries and a linear association 
with increasing duration of use. A positive association was also found between ever use of 
MHT and melanoma risk, which was heterogeneous across countries.
Our finding of a modest positive association between OC use and melanoma risk is 
consistent with the results from the analysis of national data in France (27) and from a Dutch 
population-based case-control study (30), but contrasts with the results from previous meta-
analyses (14,37) and a pooled-analysis of case-control studies (38) showing no association 
with OC use. These differences could be explained by the predominance of retrospective 
designs and small numbers of melanoma cases in most previous studies. Also, the women 
included in our study were generally older than in previous research (41 years old on 
average in Gandini et al.’s meta-analysis (14) and 61.5 years in our population). Of note, 
most studies reporting a positive association did not control for sun exposure in previous 
research (14). In a prospective study among premenopausal nurses, the association was 
positive with current use of OCs, and stronger in women reporting sunburns and skin 
sensitivity to sun exposure in childhood (Pinteraction=0.07) (39). In Gandini’s meta-analysis, 
summary estimates were slightly lower when adjusted for phenotype and sun exposure (14). 
In contrast, we did not observe any appreciable difference in the association after 
adjustment for hours of outdoor physical activity during summer in our study.
Regarding duration of OC use, we found a positive linear association with melanoma risk, 
while other studies reported no association overall (14,40). However, we found no 
association between age at first OC use and melanoma risk, consistent with previous studies 
(14).
OC use was associated with ALM risk in our study. However, this result could be due to 
chance given the small case numbers. Of note, ALM accounts for less than 5% of all 
melanoma cases worldwide, but this proportion increases up to 70% in darker skin types 
(41). The EPIC cohort lacked data on skin type or ethnicity, which might be important 
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confounders in this association. Nevertheless, the ALM tumor type has never been explored 
in relation to exogenous hormone use and should be further investigated in studies 
considering skin type or ethnicity.
In our main analyses, we found a modest positive association between MHT use and 
melanoma risk, which contrasts with the existing meta-analysis (14) and two recent US 
studies (40,42), but is consistent with three recent European cohort studies reporting 
positive associations (26,28,43). In addition, associations became stronger and statistically 
significant in our sensitivity analyses. This change in estimates likely reflects differences in 
population sample selection, since estimates were heterogeneous across countries and 
some countries were excluded from the sensitivity analyses.
We found no association between duration of MHT use or age at first use and melanoma 
risk, consistent with results from previous studies (14,40,44,45).
Several types of MHT were associated with melanoma risk in our study. We found positive 
associations with unopposed estradiol and unopposed estrogens administrated by cream. 
This is consistent with the results from the analyses of national data in France, Norway, and 
Sweden, showing a positive association with unopposed estrogens overall (mainly estradiol) 
(26,28,43). In contrast, previous US studies reported no association with unopposed 
estrogens (40,42), but it should be noted that the main type of estrogens prescribed in the 
US is conjugated equine estrogens (CEE), while the main type prescribed in European 
countries is estradiol, as reflected from the distribution in our population (except for 
Germany and the UK for which about half of opposed estrogens were CEE). This underlines 
the importance to consider the different types of estrogens in exploring the relation 
between exogenous hormone use and melanoma risk. However, it should be noted that the 
differences in type of hormones could be driven by differences across countries, although 
the three countries for which we found a stronger association (France, Spain, Germany) had 
marked differences in the type of hormone used. If confirmed, it could be hypothesized that 
the variations in these associations according to the type of hormone could be driven by a 
photosensitizing effect of some specific MHT components, as shown for ethinylestradiol 
(46).
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MHTs containing promegestone were also positively associated with melanoma risk in our 
study, consistent with the findings from the French E3N cohort (26). In sensitivity analyses, 
MHTs containing norethindrone acetate also became positively associated with melanoma 
risk. This association was not reported in Norway, where norethindrone acetate is the only 
progestogen used in opposed formulations (28), and our sensitivity analyses excluded data 
from Norway. Another difference potentially contributing to this result is that the Norwegian 
study considered time-dependent MHT exposure, while there was a single baseline 
assessment of exposure in EPIC.
For combined MHT, sequential or continuous regimens reveal different levels of exposure to 
progestogens (continuous regimens involving daily exposure during treatment), and 
compared with sequential regimens, continuous ones have been shown to confer higher 
breast cancer risk (18). We used regimen of administration, which was seldom considered in 
previous research on melanoma risk, as an additional parameter to test whether melanoma 
could be influenced by exogenous hormones. We found no association with melanoma risk, 
except for a positive association with sequential regimens in sensitivity analyses. In the 
Norwegian cohort study, a similar association was found, although with no statistical 
significance. These results do not support the hypothesis of a strong relation between the 
progestogen component of hormonal treatments and melanoma risk. Of note, our findings 
on MHT formulations overall need cautious interpretation as no heterogeneity was found 
across estimates, and they rely on few cases.
We observed heterogeneity in estimates regarding MHT use across countries. Patterns of 
MHT use vary nationally, with for instance variability in age at first use or types of exogenous 
hormones prescribed in each European country, which is influenced by national 
recommendations (16). The profile of users might also vary, and importantly, sun exposure 
may be a confounder of the relations between exogenous hormones and melanoma risk, 
which is incompletely controlled for by stratifying by center in our analyses. While our 
results were not substantially modified after adjustment for hours of recreational physical 
activity in summer, we cannot rule out confounding or effect modification by sun exposure, 
as this was only a proxy.
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In fully-adjusted models, MHT users were at higher risk of melanoma (with or without OC 
use) compared with women who never used hormonal therapies, and we found no 
association with cumulative duration of use. These results do not support a direct influence 
of cumulative hormonal exposure on melanoma risk.
Strengths of our study included the study design and availability of data on OC and MHT use 
in 10 European countries, spanning a wide diversity of hormonal formulations across Europe; 
information on melanoma site and type; and the large sample size of the EPIC cohort. 
However, one major limitation is the lack of information on risk factors for melanoma, such 
as sun exposure, pigmentary traits, family history of skin cancer, and socio-economic 
parameters such as income, hence compromising the study of a potential confounding effect 
by these factors. Although we used hours of recreational physical activity in summer as a 
proxy for time spent outdoors, the EPIC cohort did not evaluate behavioral sun exposure and 
there is high potential for residual confounding. It has indeed been suggested that 
exogenous hormone users are more prone to intentional UV exposure, with associations 
found between sunscreen use, sunburns, tanning bed use and melanoma risk (27,47). 
Another limitation is the single baseline assessment of exogenous hormone exposure from 
self-reports, which does not take into account variability in use over time and might procure 
recall bias, especially in case of past exogenous hormone use. While we had detailed data on 
MHT use, statistical power remained low in analyses over subcategories of MHT 
formulations. Data on OC use were less detailed, and did not enable a thorough analysis for 
OCs. Also, we lacked information on the reason for prescription. This could be important as 
OCs can be prescribed for conditions related to hyperandrogeny (irregular or heavy menses, 
acne, etc.) and androgens has been suspected to increase melanoma risk (48,49). Last, since 
EPIC participants were recruited at 51 years old on average, we were not able to study early-
onset melanomas, which may be important to investigate in relation to hormonal exposures 
according to a recent study (50). However, this age range of recruitment allowed the study 
of long-term effects of exogenous hormones taken earlier in life, especially for OCs.
In conclusion, the findings from this large prospective study do not support a strong and 
direct association between exogenous hormone use and melanoma risk. If the hypothesis of 
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a hormonal influence on melanoma were true, it is likely modest and thus difficult to 
disentangle from the effects of other exposures, such as exposure to UV radiation, which has 
a major impact on melanoma risk. Further research performed in large prospective cohorts 
that include detailed information on types of hormone and UV exposure - which may act as 
an important confounder or effect modifier on these relations - will help further shed light 
on these relationships and their underlying mechanisms.
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 n=334,483 n=68,612 n=31,072 n=25,321 n=54,491 n=27,409 n=15,531 n=27,877 n=20,494 n=29,010 n=34,666
Recruitment
Mean age at recruitment (SD) 51.1 (9.7) 52.7 (6.6) 50.6 (8.1) 48.3 (8.4) 47.9 (14.3) 51.0 (11.6) 53.3 (12.5) 49.1 (9.0) 55.6 (8.1) 56.7 (4.4) 48.1 (4.3)
Recruitment period 1991-2000 1993-1997 1992-1998 1992-1996 1993-2000 1993-1997 1993-1999 1994-1998 1991-1996 1993-1997 1998
Mean length of follow-up (SD) 13.9 (3.8) 12.9 (3.4) 14.3 (3.0) 16.1 (2.9) 15.1 (3.6) 14.3 (3.4) 11.1 (3.5) 10.4 (3.0) 16.9 (4.9) 15.0 (3.9) 13.3 (2.5)
Incident cutaneous melanoma cases 1,696 381 96 67 295 181 13 86 167 204 206
Level of education
None/primary 28.94 11.39 52.46 78.76 11.14 17.93 66.79 23.34 37.94 31.27 23.20
Technical/professional school 21.68 - 10.98 5.45 26.81 32.96 3.20 41.82 29.24 46.57 35.82
Secondary school 23.19 48.98 23.10 5.52 13.10 30.66 14.56 8.00 9.85 11.82 28.57
Longer education (incl. University 
degree)
22.46 35.59 13.30 9.49 32.11 18.14 15.21 26.79 22.57 10.19 12.41
Missing 3.72 4.04 0.15 0.77 16.84 0.31 0.24 0.05 0.40 0.14 -
Marital Status
Single 9.00 16.57 6.29 - 15.00 13.96 4.18 9.27 7.55 - -
Married/de facto 63.43 79.57 81.66 - 68.95 71.06 80.66 73.20 67.88 - 81.60
Divorced/Separated 4.79 - 4.89 - 9.34 8.15 2.98 12.49 15.80 - -
Widowed 3.67 - 6.32 - 6.43 6.64 12.10 5.03 8.39 - -
Missing 19.11 3.86 0.85 100.00 0.28 0.19 0.07 0.01 0.38 100.00 18.40
Age at menarche (years)
≤12 36.01 41.62 50.11 40.02 39.05 32.01 35.02 34.09 23.69 22.48 28.32
13-14 47.02 46.62 41.73 45.59 44.84 46.12 46.03 48.73 52.31 47.77 53.02
≥15 15.77 11.18 8.14 14.28 13.79 20.48 18.38 17.15 22.72 26.23 17.07
Missing 1.20 0.58 0.02 0.10 2.32 1.39 0.57 0.04 1.27 3.53 1.59
Menstrual cycle length (days)
<30 27.12 10.38 28.88 46.63 43.09 20.09 44.89 39.61 11.25 11.94 28.91
30-33 22.16 26.64 24.12 24.67 16.38 12.52 22.19 22.34 26.20 17.48 27.75
























 n=334,483 n=68,612 n=31,072 n=25,321 n=54,491 n=27,409 n=15,531 n=27,877 n=20,494 n=29,010 n=34,666
34-36 18.12 18.50 21.98 15.58 13.30 17.62 16.43 15.41 27.48 25.42 15.03
≥37 16.40 18.25 22.48 10.65 12.95 16.36 13.40 14.63 20.06 27.81 7.97
Missing 16.21 26.23 2.53 2.46 14.28 33.41 3.09 8.00 15.00 17.35 20.35
Number of full-term pregnancies
None 14.43 8.93 13.17 10.51 30.00 20.30 10.12 14.38 11.06 11.58 6.50
1 14.89 15.38 22.05 9.90 13.55 4.86 11.00 25.56 17.65 15.51 12.18
2 39.26 41.36 43.87 36.40 32.53 22.12 48.54 43.15 38.87 45.38 45.01
≥3 26.27 27.02 20.90 42.34 21.51 23.48 30.08 16.67 23.67 27.26 34.31
Menopausal status
Premenopause 34.01 26.09 39.18 53.47 49.27 32.45 36.40 46.16 7.89 7.25 35.06
Perimenopause 44.19 43.39 41.75 31.98 37.86 47.02 51.48 37.74 65.40 72.72 30.11
Postmenopause, natural 18.84 27.78 15.18 9.58 9.96 17.56 6.86 13.05 26.71 15.37 34.43
Postmenopause, artificial 2.96 2.74 3.88 4.96 2.90 2.97 5.25 3.05 4.66 0.40
Ever use of exogenous hormones
Oral contraceptives 58.43 60.90 41.04 42.17 66.95 73.05 9.54 81.12 51.74 58.26 63.80
Menopausal hormone therapy1 45.72 59.34 25.34 19.00 40.43 26.34 - 60.10 - 49.55 68.75
OC use/MHT use1
Never OC /Never MHT 34.49 27.79 58.64 65.47 42.51 32.93 - 18.58 - 25.22 16.63
Ever OC /Never MHT 19.79 12.87 16.02 15.53 17.07 40.73 - 21.33 - 25.24 14.62
Never OC /Ever MHT 19.61 29.55 15.74 12.73 15.53 8.1 - 15.93 - 20.29 27.08
Ever OC /Ever MHT 26.11 29.78 9.6 6.26 24.89 18.24 - 44.17 - 29.26 41.67
Height2
Quartile 1 24.82 24.66 45.64 57.90 19.90 12.77 57.50 18.91 14.93 13.79 4.73
Quartile 2 21.92 26.54 25.01 23.32 22.62 18.22 20.95 22.18 20.55 20.80 12.73
Quartile 3 27.25 29.44 20.15 14.26 29.03 30.19 15.07 30.93 32.73 31.71 29.16
Quartile 4 26.02 19.36 9.20 4.51 28.45 38.81 6.48 27.98 31.79 33.71 53.38
























 n=334,483 n=68,612 n=31,072 n=25,321 n=54,491 n=27,409 n=15,531 n=27,877 n=20,494 n=29,010 n=34,666
BMI (kg/m2)
<18.5 2.02 3.79 1.18 0.13 2.97 1.65 0.35 1.18 1.99 1.25 1.50
18.5-24 56.12 73.85 48.68 27.18 63.00 53.62 25.97 51.57 54.14 50.36 63.19
25-29 29.03 18.03 35.57 42.00 24.95 32.93 37.27 31.26 31.74 34.35 27.25
≥30 12.83 4.32 14.57 30.70 9.08 11.80 36.41 16.00 12.14 14.03 8.06
Smoking at inclusion
Never 55.70 66.60 53.66 71.30 60.43 40.87 73.07 55.90 50.36 43.73 34.09
Former smoker 22.70 19.09 20.13 9.86 27.96 31.36 5.40 25.56 24.66 24.61 29.08
Current smoker 19.48 8.67 26.20 18.79 10.95 27.71 17.07 18.37 24.69 31.44 31.15
Missing 2.12 5.64 0.01 0.05 0.66 0.06 4.46 0.18 0.30 0.21 5.68
Recreational physical activity during 
summer (hours/week)
<10 37.12 46.48 60.76 61.02 27.01 21.33 45.47 28.00 46.96 44.45 -
≥10 43.57 44.53 28.85 38.98 55.15 65.23 54.53 71.09 21.74 54.01 -
Missing 19.31 9.00 10.39 - 17.84 13.44 - 0.90 31.30 1.54 100
1 Among postmenopausal women (considering natural and artificial menopause)
2 Cut- off points for quartiles were 157, 161, and 166 cm for height
Page 25 of 33 International Journal of Cancer
Table 2: Description of exogenous hormone use as assessed at baseline, EPIC cohort (n = 195,437 women)
 All France Italy Spain UK Netherlands Germany Denmark Norway Greece Sweden
Among ever users of OCs n=195,437 n=41,788 n=12,751 n=10,679 n=36,481 n=20,021 n=22,615 n=16,900 n=22,116 n=1,482 n=10,604
Mean age at first OC use (SD) 25.5 (6.8) 28.6 (6.6) 28.4 (6.8) - 22.1 (5.8) 25.7 (7.4) - 27.7 (5.7) 22.5 (4.1) 26.6 (6.0) 26.4 (7.3)
Mean duration of OC use (SD) 6.4 (5.0) 6.5 (4.9) 3.9 (3.9) 3.7 (3.4) 6.5 (4.5) 7.6 (5.1) 9.5 (5.1) 7.2 (5.3) 4.6 (4.1) 2.5 (2.6) 7.6 (5.3)
OC duration (%)
≤ 5 years 45.55 38.50 74.71 76.10 44.35 20.44 28.37 45.85 69.28 86.37 40.02
>5 years 40.16 35.85 22.60 23.28 44.82 28.18 71.01 48.48 30.72 10.93 46.46
Missing 14.29 25.64 2.69 0.62 10.82 51.38 0.62 5.67 0.00 2.70 13.51
Age at first OC use (%)
≤20 years 19.96 3.81 11.02 - 49.24 27.87 - 7.80 37.89 15.18 24.09
21-23 years 14.07 12.59 13.57 - 18.35 15.09 - 15.34 27.24 17.61 17.96
24-29 years 22.16 28.24 32.22 - 16.87 26.80 - 39.83 26.81 37.58 25.21
≥30 years 19.17 27.15 40.05 - 11.85 28.18 - 35.26 6.53 27.53 30.56
Missing 24.64 28.21 3.14 100.00 3.70 2.07 100.00 1.77 1.53 2.09 2.19
Among ever users of MHT n=61,606 n=18,701 n=3,593 n=1,777 n=8,833 n=3,597 n=6,783 n=11,112 n=7,210
Status of use (%)
Current 66.77 62.57 47.31 55.26 69.42 51.38 77.69 66.12 85.40
Past 30.57 31.76 50.82 44.74 26.88 46.04 22.29 33.53 13.95
Unknown 2.65 5.67 1.86 - 3.70 2.59 0.01 0.35 0.65
Mean age at first MHT use (SD) 49.7 (5.3) 51.7 (4.9) 48.4 (5.4) 48.4 (4.6) 50.0 (6.3) 48.7 (5.9) 50.0 (4.1) 48.4 (5.1) 47.1 (4.0)
Mean duration of MHT use (SD) 4.1 (4.0) 3.6 (3.3) 2.2 (2.7) 1.8 (2.3) 4.1 (3.8) 4.2 (4.2) 4.4 (3.4) 6.0 (5.4) 3.6 (3.0)
Duration of MHT use (%)
<1 year 26.26 24.89 46.06 57.29 27.24 33.31 10.48 24.84 24.60
2-3 years 23.63 29.04 20.99 27.01 24.93 23.49 13.34 18.01 26.93
4-5 years 14.58 14.73 10.46 7.26 17.25 14.01 11.19 13.22 20.31
6-10 years 15.87 14.42 5.93 4.05 17.68 15.21 13.62 24.06 15.09
≥11 years 6.55 3.84 1.59 1.35 6.14 8.28 2.58 18.21 2.70
Missing 13.12 13.08 14.97 3.04 6.76 5.70 48.78 1.66 10.36
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Among current users of MHT n=41,137 n=11,701 n=1,700 n=982 n=6,132 n=1,848 n=5,270 n=7,347 n=6,157
Type of MHT (%)
Unopposed estrogens 21.81 12.38 30.82 30.86 29.62 39.61 25.12 25.90 14.99
Opposed estrogens 64.57 87.04 32.41 46.03 51.13 20.67 59.43 51.82 79.88
Tibolone 2.54 - 6.41 - 7.75 7.03 0.04 4.49 -
Unknown 11.08 0.58 30.35 23.12 11.51 32.68 15.41 17.79 5.13
Among current users of estrogen-only 
MHT
n=8,973 n=1,448 n=524 n=303 n=1,816 n=732 n=1,324 n=1,903 n=923
Type of estrogens (%)
Estradiol 61.58 60.64 71.18 50.17 43.83 60.52 37.39 82.24 89.27
Conjugated equine estrogens (CEE) 21.60 3.66 8.59 7.26 47.36 28.96 55.06 0.89 -
Low-potency estrogens 11.27 34.05 20.23 - 4.85 7.65 6.12 4.89 10.18
Other/unknown 5.55 1.66 - 42.57 3.96 2.87 1.44 11.98 0.54
Route of administration (%)
Oral 40.08 9.81 6.11 10.89 48.95 38.66 53.47 57.23 45.50
Cutaneous 30.22 55.39 14.12 64.36 23.79 37.16 21.53 16.29 37.05
          cream 8.78 33.84 4.01 5.28 3.47 0.27 0.08 10.25 -
          patch 21.44 21.55 10.11 59.08 20.32 36.89 21.45 6.04 37.05
Other/unknown1 29.70 34.81 79.77 24.75 27.26 24.18 25.00 26.48 17.44
Among current users of combined MHT n=26,562 n=10,185 n=551 n=452 n=3,135 n=382 n=3,132 n=3,807 n=4,918
Type of progestogen (%)
Micronized progesterone 9.36 24.17 2.18 1.11 0.03 0.79 0.06 - -
Progesterone derivative 35.66 68.71 83.85 78.98 5.33 30.10 19.57 19.02 0.73
           Dydrogesterone 8.78 21.01 18.15 - 0.93 15.45 0.13 - -
           Medroxyprogesterone acetate 
(MPA)
7.75 5.13 47.19 77.43 4.40 4.19 5.27 15.02 0.73
           Medrogestone 3.38 4.33 11.25 - - 10.47 11.33 - -
           Chlormadinone acetate 2.8 6.66 - - - - 2.14 - -
           Nomegestrol acetate 6.42 16.3 7.26 1.11 - - - - -
           Promegestone 5.24 13.64 - 0.44 - - - - -
           Cyproterone acetate 1.29 1.65 - - - - 0.7 3.99 -
Testosterone derivative 53.47 4.33 13.97 - 94.64 65.97 79.89 80.98 99.27
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           Norethindrone 38.62 4.15 13.79 - 31.32 45.29 38.63 71.37 95.1
           Norgestimate 9.65 - - - 54.16 20.68 6.86 9.61 4.17
           Levonorgestrel 5.21 0.18 0.18 - 9.15 - 34.39 - -
Other/unknown 1.51 2.79 - 19.91 - 3.14 0.48 - -
Regimen (%)
Sequential 44.38 7.06 18.51 2.88 89.82 68.06 69.28 70.92 61.18
Fixed continuous 15.45 2.12 0.73 8.23 7.59 24.43 25.09 38.19
Other/unknown 40.16 90.82 80.76 97.12 1.95 24.35 6.29 3.99 0.63
1 Including low-potency estrogens
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Table 3: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for the associations between oral contraceptive (OC) use and melanoma risk, EPIC cohort 









Never 658 ref ref
Ever 1,038 1.12 (1.01 - 1.26)* 1.12 (1.00 - 1.26)*
Duration of OC use3
Continuous (per year) 1.02 (1.01 – 1.03)* 1.02 (1.00 - 1.03)*
Never use 658 ref ref
≤5 years 458 1.12 (0.98 - 1.28) 1.11 (0.97 - 1.26)
>5 years 448 1.21 (1.06 - 1.39)* 1.20 (1.04 - 1.37)*
p-trend 0.005* 0.01*
Age at first use3
Continuous (per year) 1.01 (1.00 - 1.03) 1.01 (0.99 - 1.02)
≤20 years 172 ref ref
21-23 years 158 1.14 (0.90 - 1.44) 1.12 (0.87 - 1.43)
24-29 years 279 1.22 (0.96 - 1.54) 1.20 (0.94 - 1.53)
≥30 years 253 1.26 (0.72 - 1.41) 1.24 (0.94 - 1.64)
p-trend 0.15 0.19
* Significant at P value ≤ 0.05
1 Model 1: stratified for center and age at recruitment 
2 Model 2: model 1 with additional  adjustments for education, age at menarche, length of menstrual cycles, number of full term pregnancies, menopausal status, height, body mass index, and tobacco use
3 Totals may not add-up due to missing data: there were 27,933 (14.3%) missing values in duration of use, 48,147 (24.6%) in age at first use
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Table 4: Hazard Ratios (HRs) and 95% confidence intervals (CIs) for the associations between MHT use and melanoma risk among postmenopausal women, EPIC cohort 
(n = 134,758 women)







Never 407 ref ref
Ever 363 1.08 (0.93 - 1.27) 1.14 (0.97 - 1.35)
Status of MHT use
Never 407 ref ref
Current 244 1.10 (0.92 - 1.31) 1.18 (0.98 - 1.43)
Past 108 1.04 (0.84 - 1.29) 1.07 (0.86 - 1.34)
Unknown 11 1.34 (0.73 - 2.47) 1.36 (0.72 - 2.59)
Duration of MHT use3
Never 407 ref ref
≤5 years 228 1.06 (0.89 - 1.26) 1.12 (0.93 - 1.34)
>5 years 79 1.00 (0.78 - 1.28) 1.05 (0.80 - 1.36)
p-trend 0.88 0.42
Duration of use in ever users3
Continuous (per year) 1.01 (0.98 - 1.04) 1.01 (0.98 - 1.05)
≤1 year 79 ref ref
2-3 years 86 1.18 (0.87 - 1.61) 1.19 (0.87 - 1.63)
4-5 years 63 1.35 (0.97 - 1.90) 1.39 (0.99 - 1.96)
6-10 years 54 1.08 (0.76 - 1.54) 1.09 (0.76 - 1.57)
≥11 years 25 1.20 (0.75 - 1.94) 1.23 (0.76 - 2.01)
p-trend 0.33 0.24
Age at first  use in ever users3
Continuous (per year) 0.99 (0.97 - 1.02) 0.99 (0.97 - 1.02)
≤50 years 197 ref ref
51-52 years 26 0.93 (0.61 - 1.43) 0.94 (0.62 - 1.45)
52-55 years 71 0.99 (0.73 - 1.33) 0.97 (0.71 - 1.32)
≥ 55 years 46 0.78 (0.54 - 1.14) 0.81 (0.55 - 1.19)
p-trend 0.51 0.55
Page 30 of 33International Journal of Cancer
Type of MHT currently used4
Never 407 ref ref
Unopposed estrogens 59 1.17 (0.89 - 1.55) 1.24 (0.93 - 1.64)
           Estradiol 45 1.44 (1.05 - 1.97)* 1.53 (1.11 - 2.11)*
           CEE 8 0.76 (0.37 - 1.55) 0.81 (0.39 - 1.65)
           Weak 4 0.72 (0.27 - 1.93) 0.74 (0.27 - 1.99)
           Other/unknown estrogen 2 0.69 (0.17 - 2.77) 0.70 (0.17 - 2.83)
Estrogens combined with a progestogen 155 1.09 (0.89 - 1.35) 1.18 (0.94 - 1.48)
           Micronized progesterone 17 1.49 (0.88 - 2.51) 1.46 (0.85 - 2.51)
           Progesterone derivative 50 1.13 (0.81 - 1.56) 1.21 (0.86 - 1.71)
                      Dydrogesterone 9 0.80 (0.41 - 1.60) 0.77 (0.37 - 1.59)
                      MPA 12 1.24 (0.69 - 2.22) 1.41 (0.78 - 2.57)
                      Medrogestone 2 0.46 (0.11 - 1.86) 0.48 (0.12 - 1.95)
                      Chlormadinone acetate 6 1.89 (0.82 - 4.35) 2.03 (0.88 - 4.69)
                      Nomegestrol acetate 5 0.63 (0.26 - 1.57) 0.70 (0.28 - 1.75)
                      Promegestone 14 2.34 (1.32 - 4.15)* 2.57 (1.44 - 4.60)*
                      Cyproterone acetate 2 1.13 (0.28 - 4.57) 1.31 (0.32 - 5.34)
           Testosterone derivative 86 1.02 (0.78 - 1.33) 1.11 (0.84 - 1.48)
                      Norethindrone 61 0.96 (0.71 - 1.31) 1.05 (0.76 - 1.44)
                      Norgestimate 18 1.22 (0.74 - 2.01) 1.38 (0.82 - 2.31)
                      Levonorgestrel 7 1.08 (0.47 - 2.48) 1.22 (0.53 - 2.82)
           Other/unknown progestogen 2 1.12 (0.27 - 4.55) 1.20 (0.29 - 4.93)
Other/unknown MHT type5 30 0.96 (0.66 - 1.40) 1.04 (0.71 - 1.53)
Route of administration4,6
Never 407 ref ref
Oral 29 1.38 (0.94 - 2.03) 1.46 (0.99 - 2.16)
Cutaneous 17 1.16 (0.71 - 1.89) 1.25 (0.76 - 2.04)
           Cream 9 2.11 (1.08 - 4.12)* 2.20 (1.12 - 4.29)*
           Patch 8 0.77 (0.38 - 1.56) 0.84 (0.41 - 1.70)
Other/unknown 13 0.88 (0.50 - 1.53) 0.91 (0.52 - 1.59)
Regimen4,7
Never 407 ref ref
Sequential 69 1.00 (0.75 - 1.32) 1.12 (0.82 - 1.53)
Fixed continuous 22 0.86 (0.55 - 1.36) 0.88 (0.55 - 1.41)
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Unknown 64 1.36 (0.99 - 1.87) 1.43 (1.03 - 1.99)*
* Significant at P value ≤ 0.05
1 Model 1: stratified for center and age at recruitment
2 Model 2: model 1 with additional  adjustments for education, age at menarche, length of menstrual cycles, number of full term pregnancies, oral contraceptive use, height, body mass index, and tobacco use
3 Totals may not add-up due to missing data: there were 8,080 (13.1%) missing values in duration of use; 3,036 (5.0%) in age at first use
4 Adjusted for past use
5 Include tibolone
6 Route of administration concerns unopposed estrogens, and analyses are additionally adjusted for use of other types of therapies
7 Regimens concerns combined therapies, and analyses are additionally adjusted for use of other types of therapies
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Table 5: Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations between exogenous hormone use and melanoma risk among postmenopausal 









Never OC /Never MHT 249 34.49 ref ref
Ever OC /Never MHT 158 19.79 1.01 (0.81 - 1.24) 1.00 (0.80 - 1.24)
Never OC /Ever MHT 155 19.61 1.10 (0.89 - 1.36) 1.15 (0.93 - 1.43)
Ever OC /Ever MHT 208 26.11 1.08 (0.87 - 1.33) 1.13 (0.90 - 1.40)
Duration of OC/MHT use
Never use of OC or MHT 249 34.49 ref ref
≤ 5 years 302 39.35 1.02 (0.85 - 1.22) 1.13 (0.90 - 1.40)
6-10 years 45 5.11 1.18 (0.84 - 1.65) 1.40 (0.93 - 2.10)
>10 years 78 9.45 1.10 (0.83 - 1.45) 1.32 (0.93 - 1.89)
p-trend 0.43 0.14
Missing 96 11.60 1.15 (0.88 - 1.51) 1.38 (1.00 - 1.91)*
* Significant at P value ≤ 0.05
1 Model 1: stratified for center and age at recruitment
2 Model 2: model 1 with additional adjustments for education, age at menarche, length of menstrual cycles, number of full term pregnancies, height, body mass index, and tobacco use
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